Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.39 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793554 | 0.85 | WNK1 (0.39) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL10924129 | 0.85 | MAPK1 (0.41) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL3036505 | 0.85 | KMT2A (0.47) | KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL16782293 | 0.82 | MAPT (0.41) | KMT2AMAPTMEN1ALDH1A1WNK1 | |
| SCHEMBL5346439 | 0.82 | ATM (0.42) | KMT2AMAPTMEN1ALDH1A1WNK1 | |
| SCHEMBL29793698 | 0.82 | WNK1 (0.41) | KMT2AMAPTMEN1ALDH1A1WNK1 | |
| SCHEMBL20240595 | 0.82 | NPC1 (0.44) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL20520337 | 0.80 | HPGD (0.39) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL29502909 | 0.80 | NPBWR1 (0.46) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL18702763 | 0.80 | NPBWR1 (0.46) | KMT2AMAPTMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1910369-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007013673-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | KMT2A 547/4885MAPT 4747/4885MEN1 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.